Form 4: Lisata Therapeutics Director Granted RSUs

Lisata Therapeutics Director Gregory B. Brown was granted 30,456 restricted stock units, vesting on January 9, 2027.

Summary

• Director Gregory B. Brown of Lisata Therapeutics, Inc. (LSTA) was granted 30,456 restricted stock units (RSUs).
• The grant occurred on January 9, 2026, with a transaction price of $0.
• These RSUs will vest on January 9, 2027.
• Following this transaction, Mr. Brown beneficially owns 95,659 shares of common stock, which includes the 30,456 unvested RSUs.
• The grant was made under the Issuer's 2018 Equity Incentive Compensation Plan.

Sentiment

Score: 7

Explanation: The grant of restricted stock units to a director is generally positive as it aligns management's interests with shareholders, though it's a routine compensation event rather than a direct investment.

Positives

• The grant of 30,456 restricted stock units to Director Gregory B. Brown aligns his interests with shareholders.
• The grant is part of the company's 2018 Equity Incentive Compensation Plan, indicating a structured approach to executive compensation.

Negatives

• The transaction price for the restricted stock units was $0, meaning no direct cash investment by the director for this specific grant.

Risks

• The 30,456 restricted stock units are unvested until January 9, 2027, meaning the director does not fully own them until that date.

Future Outlook

The grant of restricted stock units with a future vesting date of January 9, 2027, indicates a long-term incentive for the director, aligning future performance with shareholder value.

Industry Context

Grants of restricted stock units are a common form of equity compensation for directors and executives in the biotechnology and pharmaceutical industry, aiming to retain talent and align long-term interests with company performance.

Comparison to Industry Standards

• The grant of restricted stock units at a $0 transaction price is standard practice for equity compensation, similar to grants observed at comparable biotech firms like Moderna (MRNA) or BioNTech (BNTX) for their executives and directors, where equity incentives are used to motivate and retain key personnel without requiring an upfront cash investment from the recipient.

Stakeholder Impact

• Shareholders: The grant aligns the director's long-term interests with shareholder value through equity ownership.

Next Steps

• The 30,456 restricted stock units are scheduled to vest on January 9, 2027.

Key Dates

Recommendation

This Form 4 reports a routine grant of restricted stock units to a director, which is a standard component of executive compensation. While it aligns the director's interests with the company's long-term performance, it does not provide new fundamental information about the company's operational or financial health that would warrant a change in investment recommendation. Investors should continue to hold based on broader company fundamentals.

Keywords

Lisata Therapeutics, LSTA, Form 4, Restricted Stock Units, RSU, Insider Transaction, Director Compensation, Equity Incentive Plan